[Peripheral Arterial Disease: When is a PCSK9 Inhibitor Useful?]

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• European Society of Cardiology guidelines recommend strict LDL-C targets (<70 mg/dL or 50% reduction) for high-risk patients, including those with peripheral arterial disease (PAD), coronary heart disease (CHD), or cerebrovascular disease.
• Achieving these targets can be challenging with maximal conventional therapy (statin + ezetemibe).
• PCSK9 inhibitors offer an option for patients who do not reach recommended LDL-C levels.

Purpose of the Study:

• To evaluate the efficacy of PCSK9 inhibitors in patients with PAD who have not achieved target LDL-C levels with conventional therapy.
• To assess the impact of PCSK9 inhibitors on cardiovascular and extremity-related endpoints in PAD patients.

Main Methods:

• Analysis of data from the Fourier study, focusing on patients with peripheral arterial occlusive disease (PAOD).
• Inclusion criteria specified patients without a history of myocardial infarction or stroke at study admission.
• Evaluation of risk reduction for cardiovascular and extremity endpoints.

Main Results:

• Patients with PAOD treated with PCSK9 inhibitors experienced a significant risk reduction in cardiovascular events (RR = 0.67, p=0.0283).
• A significant risk reduction was also observed for extremity endpoints (RR = 0.43, p=0.042).
• These findings support the use of PCSK9 inhibitors in this patient population.

Conclusions:

• PCSK9 inhibitors are effective in achieving LDL-C targets for patients with PAD when conventional therapies fail.
• Treatment with PCSK9 inhibitors significantly reduces cardiovascular and extremity event risk in PAD patients.
• German guidelines support the indication of PCSK9 inhibitors by vascular specialists like angiologists for appropriate patients.